Now showing items 1-4 of 4

    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-07)
      BACKGROUND:Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a ...
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

      Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, ZI; Jones, R; Parker, CC; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Hughes, R; McLaren, D; Lester, JF; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND; STAMPEDE Investigators (2018-05)
      Background:Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ...
    • Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. 

      Mason, MD; Clarke, NW; James, ND; Dearnaley, DP; Spears, MR; Ritchie, AWS; Attard, G; Cross, W; Jones, RJ; Parker, CC; Russell, JM; Thalmann, GN; Schiavone, F; Cassoly, E; Matheson, D; Millman, R; Rentsch, CA; Barber, J; Gilson, C; Ibrahim, A; Logue, J; Lydon, A; Nikapota, AD; O'Sullivan, JM; Porfiri, E; Protheroe, A; Srihari, NN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-05)
      Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally ...
    • Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. 

      James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; Parker, CC; Ritchie, AWS; Russell, JM; Schiavone, F; Attard, G; de Bono, JS; Birtle, A; Engeler, DS; Elliott, T; Matheson, D; O'Sullivan, J; Pudney, D; Srihari, N; Wallace, J; Barber, J; Syndikus, I; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2016-03)
      IMPORTANCE:The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ...